Psoriasis, an inflammatory skin disease, is often treated with biologic therapeutics.
To determine the real-world treatment effectiveness of risankizumab, an IL-23 inhibitor, in the treatment of moderate-to-severe plaque psoriasis.
A retrospective, observational study was conducted using the CorEvitas Psoriasis Registry for eligible adults with a diagnosis of moderate-to-severe psoriasis and persistent use of risankizumab at 12 (±3) months after initiation. Skin clearance measures and patient reported outcomes were analyzed for the entire study population and by prior biologic treatment.
Among 287 patients with persistent risankizumab use at one year, most achieved clear or clear/almost clear skin and reported significant reductions in Dermatology Life Quality Index (DLQI) scores, psoriasis symptoms (fatigue, skin pain, overall itch), and work and activity impairment.
The CorEvitas Psoriasis Registry is not necessarily representative of all adults with psoriasis in the United States and Canada and does not measure patient adherence.
Patients treated with risankizumab, regardless of prior treatment, achieved high levels of clear and clear/almost clear skin, DLQI scores of 0/1, and significant reductions in psoriasis symptoms (fatigue, skin pain, overall itch) and work and activity impairment one year after initiation.

Copyright © 2023. Published by Elsevier Inc.